Q-omics provides the consensus-scored MASP1 profile across patient tissues and cancer cell-line models. MASP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MASP1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MASP1 RNA expression shows 16,249 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, KIRC, and UCEC as cancer lineages where MASP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MASP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MASP1 survival associations across molecular data types. MASP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MASP1 RNA expression–survival associations across cancer types. High MASP1 expression shows unfavorable associations in STAD, but favorable associations in HNSC, KIRC, MESO, CESC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MASP1 RNA expression.
This table summarizes MASP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MASP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MASP1 shows lower tumor expression in BLCA, THCA, LUAD, LUSC and COAD and higher tumor expression in KIRC. The KIRC box plot shows higher MASP1 RNA expression in tumor versus normal tissue (log2 FC = +2.392, t-test p < 0.001).
This table shows molecular features associated with MASP1 in patient tissues and cancer cell lines. In patient samples, MASP1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MASP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
